1. In vivo production of psilocybin in E. coli
- Author
-
John D. Brinton, Chantal S. Monnier, Alexis L. Enacopol, Alexandra M. Adams, J. Andrew Jones, Nicholas A. Kaplan, Zhangyue Wei, and Theresa Ramelot
- Subjects
0106 biological sciences ,Hallucinogen ,Bioengineering ,Biology ,Pharmacology ,01 natural sciences ,Applied Microbiology and Biotechnology ,Psilocybin ,Metabolic engineering ,03 medical and health sciences ,chemistry.chemical_compound ,010608 biotechnology ,Escherichia coli ,medicine ,030304 developmental biology ,0303 health sciences ,Norbaeocystin ,Bioproduction ,Baeocystin ,Titer ,Metabolic Engineering ,chemistry ,Batch Cell Culture Techniques ,Psilocin ,Biotechnology ,medicine.drug - Abstract
Psilocybin, the prodrug of the psychoactive molecule psilocin, has demonstrated promising results in clinical trials for the treatment of addiction, depression, and post-traumatic stress disorder. The development of a psilocybin production platform in a highly engineerable microbe could lead to rapid advances towards the bioproduction of psilocybin for use in ongoing clinical trials. Here, we present the development of a modular biosynthetic production platform in the model microbe, Escherichia coli. Efforts to optimize and improve pathway performance using multiple genetic optimization techniques were evaluated, resulting in a 32-fold improvement in psilocybin titer. Further enhancements to this genetically superior strain were achieved through fermentation optimization, ultimately resulting in a fed-batch fermentation study, with a production titer of 1.16 g/L of psilocybin. This is the highest psilocybin titer achieved to date from a recombinant organism and a significant step towards demonstrating the feasibility of industrial production of biologically-derived psilocybin.
- Published
- 2019
- Full Text
- View/download PDF